Leading the digital transformation of life sciences with artificial intelligence and advanced analytics
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180612005679/en/
The Intelligent Platform for Life Sciences (Graphic: Business Wire)
The combined platform seamlessly delivers market-leading applications, services, and proven data science capabilities, powered by the largest global pool of research data, companies’ own CRM data, 3rd party commercial data, and real-world data sources.
Pharmaceutical, biotech, and medical device companies now have an unprecedented ability to manage and optimize value across the clinical and commercial continuum.
“Together, Medidata and SHYFT are powering customers’ digital
transformation with artificial intelligence and real-world analytics to
reduce risk, optimize revenue, and ultimately help patients,” said
The new Intelligent Platform for Life Sciences significantly enhances drug and device discovery, development and commercialization by:
- Accelerating value - Demonstrate efficacy and safety, obtain regulatory approval, and achieve peak revenue faster
- Minimizing risk - De-risk the planning and execution of clinical development and commercialization strategies
- Optimizing outcomes - Provide the best possible outcomes for patients, providers, and payers with increasingly precise therapies
“As life science companies increasingly focus on improving outcomes and
safety, the need to leverage insights across the patient life cycle to
move faster and work smarter has become paramount,” said Dr.
“SHYFT and Medidata share a common vision to transform how life science
companies harness the value of data to advance enterprise
decision-making and patient outcomes,” said SHYFT CEO and Founder,
Medidata will acquire SHYFT for a total consideration of
Conference Call and Webcast
Medidata will host a conference call with the investment community today
A replay will also be available at investor.mdsol.com, or by dialing 800-585-8367 domestically, or 404-537-3406 internationally.
During the conference call, the company will provide updated 2018 guidance to incorporate deal-related costs, assumption of ongoing operating expenses of SHYFT, and write-down of acquired deferred revenue as a result of purchase accounting. A summary of the updated guidance and reconciliation of forward-looking non-GAAP financial measures to the most comparable forward-looking GAAP measures will be posted at investor.mdsol.com.
Medidata's unified platform, pioneering analytics, and unrivaled expertise power the development of new therapies for over 1,000 pharmaceutical companies, biotech, medical device firms, academic medical centers and contract research organizations around the world. The Medidata Clinical Cloud® connects patients, physicians and life sciences professionals. Companies on the Medidata platform are individually and collaboratively reinventing the way research is done to create smarter, more precise treatments.
For more information: www.mdsol.com
SHYFT Analytics is the leading cloud data analytics platform for life
sciences with solutions designed exclusively for the pharmaceutical and
biotech industry. SHYFT’s Data Analytics Platform is the most efficient
and scalable way to transform massive amounts of complex healthcare data
into high-quality, novel and intuitive clinical and commercial insight.
SHYFT is headquartered in
Certain statements made in this press release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve significant risks and uncertainties